Abstract Infectious diseases remain a leading source of human morbidity and mortality. Recently, emerging infectious diseases are dominated by zoonoses, and eventually rising considerably. Their emergence is dependent on various factors especially, socioeconomic, environmental and ecological factors etc. Recently, the swift spread of Zika virus (ZIKV) through the Americas, simultaneously with the association of infection with microcephaly and Guillain-Barré syndrome, has strained this previously overlooked virus into the global attention. ZIKV is an emerging mosquito-borne Flavivirus, identified in rhesus monkey in 1947 in Uganda, and eventually in human in 1952. Considering the severity and recent spread over Americas, it has been declared as a public health emergency of international concern, and expected number of cases may be around three to four million. Therefore, it's important for all to assess the risk and be prepared in all possible ways before it makes a huge loss and spread globally. This news tries to discuss the possible reasons for its spread, risk assessment, and options to obliterate ZIKV.
Introduction
Emerging and reemerging infectious diseases recurrently come into notice from associations between various species. These pathogens may target humans with severe disabling diseases and remain a leading source of morbidity and mortality eventually. Their emergence is dependent on various factors especially, socioeconomic, environmental and ecological factors etc. The new emerging infectious diseases are dominated by zoonoses (60.3 %), and are rising considerably in due course of time [22] . Recently, the quick spread of Zika virus (ZIKV) through the Americas [2, 21] , including the association of infection with microcephaly [4, 23, 27] and Guillain-Barré syndrome, has fetched this previously overlooked virus into the global consideration by World Health Organization (WHO). It has recently come to worldwide concern owing to severity and recent spread to Western countries including pacific oceanic region and Brazil [9, 28, 30] . Expected number of ZIKV infection cases may be around three to four million. Earlier ZIKV outbreak has been reported in areas of Africa, Southeast Asia, and the Pacific Islands. The Pan American Health Organization (PAHO) epidemiological update reported that there was increase in congenital microcephaly and other central nervous system symptoms in the regions with active ZIKV infection [17] (http://www.paho. org/hq/index.php?option=com_content&view=article&id= 11599&Itemid=41691&lang=en).
ZIKV is a mosquito-borne Flavivirus belonging to the family Flaviviridae. It consists of single stranded positive sense RNA which is infectious. The genome is of 10,794 nucleotide long with 2 flanking noncoding regions (5 0 and 3 0 NCR) and a single long open reading frame encoding a polyprotein:
0 , that is cleaved into capsid (C), precursor of membrane (prM), envelope (E) and seven non-structural proteins (NS) [6, 28] .
Many members of the genus Flavivirus are the agents of important diseases of humans, livestock, and wildlife [13] . These viruses are often maintained in complex cycles involving vertebrates such as mammals or birds, pigs and blood-feeding vectors etc. ZIKV is believed to be transmitted to humans by infected mosquitoes (Fig. 1) , of Aedes species (A. aegypti, A. albopictus, A. furcifer, A. taylori, A. luteocephalus and A. africanus) similarly as dengue and chikungunya viruses [3, 19] . Blood-feeding female Aedes mosquito injects the virus into human skin, followed by infection of permissive cells. Apart from mosquito-to-human transmission, ZIKV infections have been documented through intrauterine transmission resulting in congenital infection. Transmission from a viremic mother to her newborn was documented during 2013 outbreak in French Polynesia [25] . During Tahiti outbreak in 2013 it was reported that it can transmitted through sexual contact from an infected individuals [1, 14] . Most recent report confirmed the vertical transmission of ZIKV from mother to fetus [26] . 
Incidence and distribution

Entry receptors for ZIKV
The first step of Flavivirus entry into a host cell is mediated by the viral envelope protein. Envelope protein interacts with cell surface receptors and attachment factors of the host, whose differential expression determines the cellular tropism, and thus of pathogenesis. Aedes mosquito deposits the virus in the epidermis and dermis of the bitten host during a blood meal. Skin fibroblasts, immature dendritic cells, and epidermal keratinocytes were found to be highly permissive to infection with ZIKV [18] . Heparan sulfate act as a nonspecific attachment factor of Flaviviruses, as it concentrates viral particles on the cell surface and facilitates their interaction with primary receptors [7] . The primary receptors includes C-type lectin receptors, such as the dendritic cell-specific intracellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), the C-type lectin domain called family 5 member A (CLEC5A), TIM and TAM (Tyro3, Axl, and Mer) proteins. It was reported that DC-SIGN, AXL, Tyro3, and, to a lesser extent, TIM-1, permitted ZIKV entry, with a major role for the TAM receptor AXL. The role of these receptors in ZIKV entry was confirmed by the use of a neutralizing antibody and specific RNA silencing [18] . Virus replication occurs in the cellular cytoplasm [29] .
Clinical signs
Clinical pictures range from asymptomatic cases to an influenza-like syndrome associated to mild fever (37.8-38.5°C), non-purulent conjunctivitis, headache, arthralgia, notably of small joints of hands and feet, myalgia, asthenia, maculo-papular rash and less frequently, retro-orbital pain, anorexia, vomiting, diarrhea and abdominal pain. These symptoms normally last for 2-7 days [5, 11, 20] . Incubation period for ZIKV is still not known.
Biological confirmation of ZIKV infections is based mostly on detection of virus RNA in serum by using reverse transcription PCR, virus isolation or the detection of ZIKV specific IgM or IgG antibodies through serological tests [15] . ZIKV RNA was also detected in saliva and urine [16, 24] . There is neither vaccine to prevent nor specific anti-viral treatment available for ZIKV infection. Treatment is directed primarily at relieving symptoms using anti-pyretics that can reduce the fever and analgesics which relieves from joint and muscle pains. Additional treatment includes taking plenty of water, which can reduce the viral load in the body. 
Risk assessment for ZIKV
One of the prime responsibilities of any government is to look after the health and safety of its citizens. There are three key elements of health security: prevention wherever possible, early identification, and timely effective response. Although many countries manage infectious disease threats better than in the past, these enhancements have regularly been small in scale and limited in scope. It's important for every country to assess the risk of the particular disease before it makes a huge loss and spread globally. In the past 20 years arthropod-borne viral diseases are unexpectedly moving towards Western hemisphere from their putative origin from Asia and Africa. This clearly indicates that international concern is required about the emerging infectious disease. ZIKV is most likely maintained in a sylvatic cycle with cyclic epizooty connecting non-human primates and mosquitoes. The serological surveys indicated a silent circulation and antibodies have been detected in various animals including large mammals such as orangutans, zebra, elephants, water buffalo and rodents in West Africa and South-east Asia [12] . Moreover, the accelerated pace of globalization amplifies the risks: an outbreak anywhere is a threat everywhere. So, risk assessment and preventive steps need to be taken up immediately by governments and international bodies to counteract the ZIKV spread. Recently WHO has launched a global strategic response framework and joint operations plan to guide the international response to the spread of ZIKV infection and the neonatal malformations and neurological conditions associated with it (http://www.who.int/mediacentre/factsheets/zika/en/).
Immediate steps to be taken
The worldwide funds to counter disease emergence are poorly allocated. Reinforcing the health-care systems and immediate response from international bodies such as WHO and CDC etc., will be the best defense against outbreaks of any emerging infectious diseases which are potential international concern. In case of many viral infections, the outbreak had occurred in poor countries where there were no proper healthcare systems. However, building better health-care systems will take long time and requires human source and finances. Therefore, wealthy countries should support the poor countries for better development of health-care systems, since the spread of disease chances are there to every corner globally.
There is an urgent need to get serious about tracking ZIKV i.e., there should be proper surveillance. Mosquito control programs should be implemented immediately. Pregnant women should avoid traveling to the place where ZIKV is circulating. Public awareness programs about the ZIKV disease symptoms and precautions need to be speeded up. Blood safety authorities should consider the rescheduling of donors with a related travel history to the areas with active ZIKV transmission. Along with above mentioned points, it is important to pace up the study for specific antiviral search against ZIKV. For these doctors, scientists having expertise in infectious diseases, and other areas of biology should work collaboratively to conduct the preclinical studies and every other passageway needs to be examined to fight viral diseases.
